Jones Charles H, Hakansson Anders P, Pfeifer Blaine A
Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.
Department of Microbiology and Immunology, University at Buffalo, The State University of New York, Buffalo, NY 14260-4200, USA.
J Mater Chem B. 2014;46:8053-8068. doi: 10.1039/C4TB01058B. Epub 2014 Sep 12.
The development of safe and effective vaccines for the prevention of elusive infectious diseases remains a public health priority. Immunization, characterized by adaptive immune responses to specific antigens, can be raised by an array of delivery vectors. However, current commercial vaccination strategies are predicated on the retooling of archaic technology. This review will discuss current and emerging strategies designed to elicit immune responses in the context of genetic vaccination. Selected strategies at the biomaterial-biological interface will be emphasized to illustrate the potential of coupling both fields towards a common goal.
开发安全有效的疫苗以预防难以捉摸的传染病仍然是公共卫生的优先事项。免疫接种以对特定抗原的适应性免疫反应为特征,可通过一系列递送载体引发。然而,目前的商业疫苗接种策略基于对陈旧技术的改造。本综述将讨论在基因疫苗接种背景下旨在引发免疫反应的当前和新兴策略。将重点介绍生物材料-生物学界面的选定策略,以说明将这两个领域结合起来实现共同目标的潜力。